Compare Mesoblast Limited (MESO) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Ross Stores, Inc. — how do they compare? Mesoblast Limited trades at $14.3 (market cap $1.75B), while Ross Stores, Inc. trades at $222.86 (market cap $71.94B). The key difference: Ross Stores, Inc. is far larger — about 41.1× Mesoblast Limited's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Ross Stores, Inc. for 48 Days on average.
| MESO | ROST | |
|---|---|---|
Market Cap | $1.75B | $71.94B |
Volume | 239,027 | 2,002,519 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $255.23 |
52-Week Low | $13.19 | $147.71 |
Typical Hold Time | 15 Days | 48 Days |
Enterprise Value | $1.83B | $72.39B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Ross Stores (ROST) trades at $222.41, down 1.38% amid broader market weakness. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability metrics including 42.63% ROE and 10.85% net margin. Technical indicators signal bearish momentum with the price near key support at $221, while analyst consensus remains bullish with a $274.14 price target. Recent news highlights store expansion initiatives and strong closeout supply positioning the company for growth.
ROST presents a compelling investment case with strong operational performance and analyst confidence, though near-term technical weakness and competitive pressures warrant caution. The 16% upside to consensus target offers potential reward, but investors should monitor execution of expansion plans and consumer spending trends given the bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
